Compare VBNK & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VBNK | MDXG |
|---|---|---|
| Founded | 1980 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 622.7M | 625.6M |
| IPO Year | 2016 | 2007 |
| Metric | VBNK | MDXG |
|---|---|---|
| Price | $19.84 | $4.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $13.00 | $9.00 |
| AVG Volume (30 Days) | 79.0K | ★ 1.1M |
| Earning Date | 06-03-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.41% | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,630,000.00 |
| Revenue This Year | $30.02 | N/A |
| Revenue Next Year | $27.30 | $13.02 |
| P/E Ratio | $25.91 | ★ N/A |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $10.85 | $3.03 |
| 52 Week High | $24.42 | $7.97 |
| Indicator | VBNK | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 51.99 | 63.54 |
| Support Level | $18.90 | $4.11 |
| Resistance Level | $20.56 | $5.31 |
| Average True Range (ATR) | 0.49 | 0.15 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 64.59 | 71.09 |
VersaBank is a Schedule I Canadian bank that provides mainly commercial lending and banking services to select niche markets in Canada and the United States. Its products and services include credit assets, deposits, and cybersecurity services through its wholly owned subsidiary. The bank operates through four segments: Digital Banking Canada and Digital Banking USA, both using a business-to-business model with proprietary financial technology to serve underserved markets; DRTC, which provides cybersecurity services and banking and financial technology development; and Digital Meteor, which owns proprietary technology supporting next-generation digital assets, including Real Bank Deposit Tokens (RBDTs). The majority of revenue comes from Digital Banking.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.